Drug Profile

App2 M1

Alternative Names: Aap2-M1; App2‐M1

Latest Information Update: 25 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Dec 2023 Discontinued - Preclinical for Gram-negative infections in USA (Parenteral) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
28 Sep 2023 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
03 Sep 2019 Pharmacodynamics data from an ex-vivo study in Gram-negative infections presented at the American Society of Microbiology and European Society of Clinical Microbiology and Infectious Disease (ASM-ESCMID-2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com